Medical artificial intelligence company Lunit announced that it won CE Mark approval for its Lunit Insight CXR up-to-date chest X-ray analysis AI.
The Seoul-based company said its Lunit Insight CXR is designed to help increase accuracy for detecting more findings and alleviate the burden on radiologists who conduct routine chest X-ray procedures.
Lunit Insight CXR is capable of detecting 10 major chest abnormalities, including nodule, calcification, pneumothorax, consolidation, fibrosis and more, while also supporting tuberculosis screening. The device detects these abnormalities with an average accuracy of 98.7%, according to a news release.
The device presents its AI analysis results on the chest X-ray image, offering the location information and abnormality score while generating case reports to summarize each evaluation.
“We are delighted to announce that one of our most mature products, Lunit Insight CXR, has won CE Marking,” Lunit CEO Dr. Brandon Suh said in the release. “We look forward to installations among hospitals across Europe, where an improvement in healthcare services in the region can greatly impact many people’s lives.”
“Lunit Insight CXR has been evolving ever since its first introduction at RSNA 2017,” added Lunit head of chest radiology Sunggyun Park. “According to our reader study published in Radiology, our product can greatly improve reader performance by 20% at the highest. It can support radiologists to gain efficiency in the day to day workflow.”